Showing 8191-8200 of 8647 results for "".
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Draper James and VSP Eyes of Hope Commit Nearly $4 Million to Fund Eye Care and Eyewear in Support of Young Womenhttps://modernod.com/news/draper-james-and-vsp-eyes-of-hope-commit-nearly-4-million-to-fund-eye-care-and-eyewear-in-support-of-young-women/2476637/More women than men are at risk for vision loss from eye diseases like glaucoma and macular degeneration. To help ensure more women have access to critical eye care, Draper James, the Southern-inspired lifestyle brand founded by Reese Witherspoon, announced a partne
- Phase 1/2 Study Evaluating THR-317 for DME Meets Primary Safety Endpointhttps://modernod.com/news/data-from-phase-1-2-clinical-study-evaluating-thr-317-anti-plgf-for-dme-presented-at-2019-floretina-meeting/2476638/Oxurion NV announced that clinical-stage data from a phase 1/2 study evaluating its anti-placental growth factor candidate THR-317 for the treatment of diabetic macular edema (DME) were presented at the FLORetina 2019 meeting in Florence, Italy. THR-317 (anti-PlGF) is a recombinant humanized mono
- Eyenovia Enrolls First Patient in Phase 3 CHAPERONE Study for Progressive Myopiahttps://modernod.com/news/eyenovia-enrolls-first-patient-in-phase-3-chaperone-study-for-progressive-myopia/2476629/Eyenovia announced that it has initiated its MicroPine phase 3 program with the first patient enrolled in its CHAPERONE study, a US-based, multicenter, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. CHAPERO
- Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugshttps://modernod.com/news/verseon-showcases-oral-candidates-for-next-generation-diabetic-eye-disease-drugs/2476626/Verseon presented a new class of oral candidate drugs which could change the treatment and prevention of diabetic macular edema (DME). “Our oral development candidate, a novel inhibitor of plasma kallikrein, has the potential to redefine how DME is treated,” Dr. Anirban Datta, Verse
- Seniors With Vision Loss Experience Discrimination, Depressionhttps://modernod.com/news/seniors-with-vision-loss-experience-discrimination-depression/2476623/Seniors with declining vision are more likely than peers with good eyesight to experience discrimination as well as depression that may result from this bias, a new study from the UK suggests, according to a Reuters report. After s
- Precision Medicine to Prevent Glaucoma-Related Blindnesshttps://modernod.com/news/precision-medicine-to-prevent-glaucoma-related-blindness/2476617/Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine.
- A Third of Reviews of Corneal-Disease Treatments Not Reliablehttps://modernod.com/news/a-third-of-reviews-of-corneal-disease-treatments-not-reliable/2476611/A third of the systematic reviews of corneal-disease treatments are unreliable, according to a new study, Reuters reports. “The present investigation reveals a cause for concern. It contributes to the evidence that only a fra
- Lens Replacement Because of Cataracts May Improve Sleephttps://modernod.com/news/lens-replacement-because-of-cataracts-may-improve-sleep/2476610/Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates the body’s internal clock, according to a Reuters
- Central Retinal Vein Occlusion Rarely Complicates Ulcerative Colitishttps://modernod.com/news/central-retinal-vein-occlusion-rarely-complicates-ulcerative-colitis/2476609/Central retinal vein occlusion (CRVO) can rarely complicate the course of inflammatory bowel disease (IBD), according to a case series, as reported by Reuters. As many as 11.8% of patients with IBD can develop ophthalmological compl